Gilead Sciences and its partner Merck & Co. have officially announced the discontinuation of their Phase 3 Evoke-03 clinical trial (also designated as Keynote-D46). Following an explicit recommendation from an independent Data Monitoring Committee, the joint venture pulled the plug on the study after Trodelvy, Gilead’s first-in-class TROP2-targeted antibody-drug conjugate (ADC), failed to deliver its primary clinical objectives. The clinical setback structurally narrows the industry race to commercialize a TROP2 ADC for previously untreated first-line non-small cell lung cancer (NSCLC) cohorts.
The documented trial specifications, corporate financial impacts, and competitive market landscapes feature:
-
Clinical Readouts and Efficacy Shortfalls of the Evoke-03 Trial:
-
Evaluation Parameters: The Phase 3 trial evaluated the therapeutic efficacy of combining Trodelvy with the blockbuster anti-PD-1 therapy Keytruda as a first-line intervention for patients presenting with treatment-naive, PD-L1-high NSCLC, benchmarked against standard-of-care Keytruda monotherapy.
-
Metric Misses: At the definitive final analysis, the combination regimen failed to meet its primary endpoint of progression-free survival (PFS), despite the observation of a localized positive trend. Furthermore, an interim analysis tracking overall survival (OS) indicated the trial was statistically highly unlikely to establish significance. The disclosure drove a 2.7% drop in Gilead’s share price during Tuesday morning trading.
-
-
Financial Repercussions and Corporate M&A Transitions for Gilead:
-
Valuation Pressures: The Evoke-03 flop constitutes a massive commercial blow to Trodelvy’s long-term revenue roadmap, compound-ing a prior Phase 3 setback in second-line NSCLC more than two years ago and a voluntary market withdrawal in bladder cancer executed in 2024. Financial analysts at Jefferies and Leerink Partners noted that Trodelvy’s commercial viability will now reside almost exclusively within the triple-negative breast cancer segment. This market alone is deemed insufficient to justify the $21 billion valuation Gilead deployed to purchase the drug’s original developer, Immunomedics.
-
Strategic Pipeline Pivot: To realign investor sentiment, Gilead recently closed a significantly more capital-efficient acquisition of ADC biotech Tubulis for $3.15 billion upfront. The deal injects a novel ADC platform and the asset TUB-040 (a NaPi2b ADC holding best-in-disease potential in ovarian cancer with forward upside in NSCLC) into its pipeline. At present, Trodelvy’s remaining near-term Phase 3 readout is confined to the Ascent-GYN study in second-line endometrial cancer, scheduled for later this year.
-
-
Competitive Landscape and R&D Strategies of Global Rivals:
-
Merck’s Sac-TMT Integration: Wall Street analysts remain highly optimistic regarding Merck’s rival TROP2 ADC, sac-TMT (co-developed with Kelun-Biotech). Subgroup readouts from the positive OptiTROP-lung05 study associated the sac-TMT and Keytruda combination with a profound 53% PFS benefit over Keytruda alone in Chinese patient cohorts. Sac-TMT delivers superior numerical efficacy benchmarks and exhibits a superior tolerability profile, tracking a treatment-related discontinuation rate below 10%, compared to the 24% discontinuation rate logged by Trodelvy in Gilead’s Phase 2 Evoke-02 study. Merck is aggressively advancing the global Phase 3 TroFuse-007 trial to validate this regimen.
-
AstraZeneca and Daiichi Sankyo’s Datroway Asset: The multinational alliance is aggressively targeting the lucrative first-line NSCLC market via its closely watched Phase 3 Avanzar trial evaluating its TROP2 ADC, Datroway, with data readouts projected within the year. To optimize clinical probability of success, AstraZeneca has pioneered a proprietary TROP2-based biomarker selection framework. This diagnostic methodology is currently deployed within its parallel Tropion-Lung08 trial, testing Datroway alongside Keytruda in nonsquamous, PD-L1-high first-line NSCLC populations.
-